ライフサイエンスコーパス: angioplasty

1 went DCB angioplasty or conventional balloon angioplasty.

2 repopulation of stented blood vessels after angioplasty.

3 ary artery bypass graft surgery, stents, and angioplasty.

4 superior compared with conventional balloon angioplasty.

5 ry branch occlusion during elective coronary angioplasty.

6 h a paclitaxel-coated balloon or to standard angioplasty.

7 fits of cardiovascular interventions such as angioplasty.

8 a dedicated bifurcation stent or SB balloon angioplasty.

9 easing the risk of late thrombosis following angioplasty.

10 ncy among patients undergoing infrapopliteal angioplasty.

11 magnetic resonance (MR) imaging 3 days after angioplasty.

12 following percutaneous transluminal coronary angioplasty.

13 served in 5% of patients during test balloon angioplasty.

14 tery revascularization compared with balloon angioplasty.

15 crophage invasion, and TLR4 expression after angioplasty.

16 ated balloon angioplasty or uncoated balloon angioplasty.

17 restenosis compared to conventional balloon angioplasty.

18 of DCB angioplasty over conventional balloon angioplasty.

19 both strategies compared to standard balloon angioplasty.

20 ove vessel patency after superficial femoral angioplasty.

21 acute aneurysm formation was 0% to 13% after angioplasty, 0% to 5% after bare metal stent placement,

22 s, mortality was similar after plain balloon angioplasty (12.6%) and paclitaxel-coated balloon angiop

23 d 104 were treated with conventional balloon angioplasty (18.5%).

24 rogressively declined from plain old balloon angioplasty (341% increase) to bare metal stent (218% in

25 rs consisted of 13 bypasses (4.3%), 18 patch angioplasties (6.0%), and 79 primary repairs (26.4%).

26 mong patients who had undergone conventional angioplasty (65.2% vs. 52.6%, P=0.02).

27 plasty (12.6%) and paclitaxel-coated balloon angioplasty (9.6%; HR=0.84 [95% CI, 0.66-1.06], P=0.14).

28 ized DAPA trial (Defibrillator After Primary Angioplasty) aimed to evaluate the survival benefit of p

29 taxel-coated balloon was superior to balloon angioplasty alone with a late loss of 0.43 +/- 0.61 mm v

30 er endovascular treatment for CoA, including angioplasty alone, bare metal stenting, and primary cove

31 consider for future clinical trials include angioplasty alone, indirect surgical bypass procedures,

32 Percutaneous angioplasty along with metallic stent placement has been

33 gioplasty compared with conventional balloon angioplasty (also known as plain old balloon angioplasty

34 elevation MI successfully treated by primary angioplasty and 16 matched controls were prospectively r

35 nfidence interval [CI]: 80.4%, 95.2%) of DCB angioplasty and 62.7% (95% CI: 50.0%, 73.0%) of conventi

36 urred in 97.2% (95% CI: 89.1%, 99.3%) of DCB angioplasty and 78% (95% CI: 66.5%, 86.0%) of convention

37 s, vessel remodeling during restenosis after angioplasty and atherosclerosis.

38 Studies from the balloon angioplasty and bare metal stent eras have demonstrated

39 sadvantages and limitations of plain balloon angioplasty and bare-metal stents, some limitations appl

40 simultaneous right ventricular outflow tract angioplasty and CA angiography.

41 Coronary interventions, including balloon angioplasty and coronary stent implantation, are associa

42 tion, and emergent coronary angiography with angioplasty and intravascular US were performed ( Fig 1

43 tion, and emergent coronary angiography with angioplasty and intravascular US were performed.

44 Angioplasty and stent implantation have become accepted

45 ena cava (IVC) and iliocaval confluence with angioplasty and stent implantation is very rare.

46 treat atherosclerosis, such as transluminal angioplasty and stent implantation, often cause vascular

47 Thirty-five patients underwent an angioplasty and stent implantation; 3 had cardiac surger

48 a cohort of 284 patients undergoing coronary angioplasty and stent placement (rs350099: TT versus CC+

49 on of iliofemoral stenosis or occlusion with angioplasty and stent placement has been increasingly us

50 Angioplasty and stent placement in right ventricle-to-pu

51 graphy and 20 patients treated with coronary angioplasty and stent placement.

52 gnificantly lower in patients treated by PEB angioplasty and stenting (34+/-31%) as compared with BA

53 and stenting (34+/-31%) as compared with BA angioplasty and stenting (56+/-29%, P=0.009) or DA (55+/

54 Restenosis after balloon angioplasty and stenting (BAS) remains an unsolved clini

55 with carotid endarterectomy (CEA) or carotid angioplasty and stenting (CAAS), the benefits from medic

56 efficacy, safety, and durability of carotid angioplasty and stenting (CAS) have been better defined

57 ain balloon angioplasty (BA) followed by PEB angioplasty and stenting (n=48), BA and stenting (n=52),

58 l group versus the percutaneous transluminal angioplasty and stenting (PTAS) group (p=0.0252).

59 tid revascularization with endarterectomy or angioplasty and stenting are established treatments for

60 Our results suggest that HAS angioplasty and stenting are minimally invasive and safe

61 Balloon angioplasty and stenting are the mainstays of endovascul

62 or target lesion revascularization after PEB angioplasty and stenting as compared with BA and stentin

63 Balloon angioplasty and stenting form the backbone of endovascul

64 reover, endovascular drug delivery following angioplasty and stenting has been achieved with a marked

65 on lesion modification to facilitate balloon angioplasty and stenting has underpinned major advances

66 level 1 evidence comparing open bypass with angioplasty and stenting in TransAtlantic Inter-Society

67 superficial femoral artery lesions with PEB angioplasty and stenting is superior to BA angioplasty a

68 Angioplasty and stenting is the primary treatment for fl

69 The Revascularization With Open Bypass vs Angioplasty and Stenting of the Lower Extremity Trial (R

70 B angioplasty and stenting is superior to BA angioplasty and stenting or DA in terms of angiographic

71 omized and receive percutaneous transluminal angioplasty and stenting or femoropopliteal bypass, resp

72 adverse outcomes in the ACT-1 trial (Carotid Angioplasty and Stenting Versus Endarterectomy in Asympt

73 Adjunctive angioplasty and stenting was performed in 19 (80%) patie

74 ndothelialization in a rat model of arterial angioplasty and stenting.

75 cation predicts accelerated restenosis after angioplasty and stenting.

76 rtic valvuloplasty; coarctation of the aorta angioplasty and stenting; and pulmonary artery stenting.

77 opliteal bypass or percutaneous transluminal angioplasty and stenting; patients with TASC II A and D

78 One DCB angioplasty and two conventional balloon angioplasty par

79 Frequency of angioplasty and vascular stent implantation procedures i

80 f infrapopliteal interventions using balloon angioplasty and/or bare stents are limited by a relative

81 ents, -24.2% (-32.2 to -16.4) versus balloon angioplasty, and -31.8% (-44.8 to -18.6) versus rotablat

82 dies of the use of percutaneous transluminal angioplasty as primary treatment for patients with infra

83 osis after intervention using either balloon angioplasty (BA) alone or BA with stenting.

84 e randomized to treatment with plain balloon angioplasty (BA) followed by PEB angioplasty and stentin

85 An angioplasty balloon (1.5-2x6 mm) was used to deliver 1 t

86 With A Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon), 300 symptomatic patients (Rutherfo

87 cokinetic Study of the Stellarex Drug-Coated Angioplasty Balloon), paclitaxel plasma concentrations w

88 after full effacement of the stenosis by the angioplasty balloon.

89 associated with the use of paclitaxel-coated angioplasty balloons and stents in lower-limb endovascul

90 Drug-coated angioplasty balloons deliver antiproliferative agents di

91 on-DCB devices (such as conventional balloon angioplasty, bare-metal stents, or drug-eluting stents)

92 There remains a limited role for angioplasty because this intervention does not address t

93 k patients in registries have masked primary angioplasty benefit?

94 weeks after percutaneous transluminal, renal angioplasty blood pressure was normalized in all animals

95 pulmonary vasodilators or balloon pulmonary angioplasty (BPA).

96 duit tears are common in patients undergoing angioplasty, but clinically important tears, which only

97 rtery stenosis and were treated with balloon angioplasty by radiology.

98 To assess 2-year efficacy and safety of DCB angioplasty compared with conventional balloon angioplas

99 cular event (myocardial infarction, coronary angioplasty, coronary artery bypass graft surgery, strok

100 Drug-coated balloon angioplasty (DCBA) was shown to be superior to standard

101 ficial femoral artery," "popliteal artery," "angioplasty," "drug-eluting balloon," "paclitaxel-elutin

102 rial intima hyperplasia and restenosis after angioplasty, especially in diabetes.

103 n Peripheral Intervention for below the knee angioplasty evaluation (DEBATE-BTK) is a randomized, ope

104 Compared with balloon angioplasty, everolimus-eluting stent (hazard ratio [95%

105 rved predominantly for primary and secondary angioplasty failures.

106 was significantly lower in patients with PCB angioplasty for BMS restenosis compared with DES resteno

107 e prospectively enrolled patients undergoing angioplasty for dialysis access dysfunction.

108 The efficacy of balloon angioplasty for native CoA during infancy beyond the neo

109 e review of 68 infants who underwent balloon angioplasty for native CoA.

110 Balloon angioplasty for native coarctation of the aorta (CoA) is

111 (Primary Angioplasty for STEMI During COVID-19 Pandemic [ISACS-ST

112 On day 2 after successful primary angioplasty for STEMI, 53 patients were prospectively en

113 porary outcomes of percutaneous transluminal angioplasty for the treatment of infrapopliteal atherosc

114 on the effects of percutaneous transluminal angioplasty for the treatment of infrapopliteal lesions.

115 balloon angioplasty was superior to standard angioplasty for the treatment of stenotic lesions in dys

116 ral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Art

117 angioplasty was superior to uncoated balloon angioplasty for treatment of bare-metal stent (BMS) and

118 allocation of higher-risk patients, primary angioplasty gave 22% lower mortality (odds ratio, 0.78;

119 han in the percutaneous transluminal balloon angioplasty group (44.9%, P=0.002).

120 nts in the percutaneous transluminal balloon angioplasty group and 77% in the nitinol stent group sho

121 m in the cryoplasty and conventional balloon angioplasty groups, respectively (p=0.02).

122 vascular treatment, percutaneous endoluminal angioplasty has become particularly attractive for arter

123 such as atherosclerosis and restenosis after angioplasty, how control of VSMC phenotypic switching is

124 acement to percutaneous transluminal balloon angioplasty in patients with peripheral artery disease R

125 atic carotid stenosis (Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid

126 nvestigation With Optimal Medical Therapy of Angioplasty in Stable Angina).

127 nction after percutaneous transluminal renal angioplasty in swine RAS.

128 d a major advancement over plain old balloon angioplasty in the management of coronary artery disease

129 ortant tears, which only occurred during UNC angioplasty in this series, were uncommon.

130 Balloon angioplasty increased the CoA diameter from 2.7+/-1 mm t

131 nds PTCA [percutaneous transluminal coronary angioplasty] inflations/deflations)+PCI (n=65) versus ro

132 Common carotid artery (CCA) balloon angioplasty injury was performed in rats.

133 een achieved RF goals in the BARI 2D (Bypass Angioplasty Investigation Revascularization 2 Diabetes)

134 coronary angiography with simultaneous test angioplasty is an important step to evaluate for the pre

135 elective percutaneous transluminal coronary angioplasty is associated with myocardial ischemic damag

136 (GFR) after percutaneous transluminal renal angioplasty is difficult.

137 Angioplasty is increasingly more often used for correcti

138 Balloon angioplasty is inferior to all drug-eluting treatments f

139 rtery disease with percutaneous transluminal angioplasty is limited by the occurrence of vessel recoi

140 Balloon angioplasty is not different from cutting balloon (0.73

141 Standard percutaneous transluminal angioplasty is the current recommended treatment for dys

142 aclitaxel drug-coated balloon (DCB) catheter angioplasty is the preferred treatment for revasculariza

143 pment of thrombosis and abrupt closure after angioplasty is well recognized.

144 With the advent of thrombolytic therapy and angioplasty, it has become possible to reduce myocardial

145 ultrasound guidance during dialysis fistula angioplasty lead to cause more and more frequent employm

146 ities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claud

147 id revascularization and carotid stenting or angioplasty (low and insufficient SOE, respectively).

148 myocardial infarction reperfused by primary angioplasty (<12 hours after symptom onset) in this card

149 Intentional fracture with UHP balloon angioplasty may be considered when treating stents that

150 Below the knee, angiosome-directed angioplasty may lead to greater wound healing, but faili

151 In a rat venous patch angioplasty model, control patches developed robust neoi

152 stenosis in a porcine femoral artery balloon angioplasty model.

153 stenosis in a porcine femoral artery balloon angioplasty model.

154 response to injury in a rat carotid balloon angioplasty model.

155 apy (MT) and percutaneous transluminal renal angioplasty (MT + PTRA) (n = 11, 3 bilaterally, n = 14 k

156 nded end-to-end anastomosis (n = 632), patch angioplasty (n = 72), interposition grafting (n = 49), b

157 was compared between 3 groups; plain balloon angioplasty (N=2104) versus paclitaxel-coated balloon an

158 ty (N=2104) versus paclitaxel-coated balloon angioplasty (N=3543), bare-metal stenting (N= 2045) vers

159 us Bare Metal Stents in Saphenous Vein Graft Angioplasty; NCT01121224) prospective, double-blind, ran

160 alloon aortic valvuloplasty, and stenting or angioplasty of Blalock-Taussig shunts.

161 Acute hemodynamic changes after angioplasty of homografts with UNC balloons included sig

162 The 1-year restenosis rate after balloon angioplasty of long lesions in below-the-knee arteries m

163 Balloon angioplasty of native CoA is effective and safe in infan

164 Safety and efficacy of angioplasty of obstructed RV-PA homografts using ultra-n

165 analyzed in 109 patients undergoing elective angioplasty of right or circumflex coronary arteries.

166 012, 70 patients underwent 76 procedures for angioplasty of RV-PA homografts with UNC Atlas balloons.

167 Stenosis trial, Stent-Protected Percutaneous Angioplasty of the Carotid Artery versus Endarterectomy

168 of the main branch with our without balloon angioplasty of the side branch offers hemodynamic advant

169 The patient underwent balloon angioplasty of the stenotic SVC segment with resolution

170 giography; 119/137 (86.9%) were treated with angioplasty, of which 113/137 (82.5%) were stented.

171 Primary angioplasty offers a less invasive option for specific a

172 Since the first coronary angioplasty on Sept 16, 1977, the field of percutaneous

173 creased all-cause mortality included balloon angioplasty or bare-metal stent placement compared with

174 Participants underwent DCB angioplasty or conventional balloon angioplasty.

175 cal progression to percutaneous transluminal angioplasty or loss of patency during 12-month follow-up

176 ver, prior trials compared CABG with balloon angioplasty or older generation stents, and it is not kn

177 angioplasty (also known as plain old balloon angioplasty or POBA).

178 r, and measures protective against AWI after angioplasty or stent implantation for CoA.

179 onary artery (CA) compression during balloon angioplasty or stent placement in the overlying conduit.

180 and LDL cholesterol values, and intracranial angioplasty or stent placement, or both, in selected pat

181 branch stenting without side branch balloon angioplasty or stenting provided the most favorable hemo

182 long-term results for freedom from coronary angioplasty or stenting, renal dysfunction, diabetes mel

183 75 mg daily, before and after infrainguinal angioplasty or stenting.

184 coronary artery to paclitaxel-coated balloon angioplasty or uncoated balloon angioplasty.

185 grafting, percutaneous transluminal coronary angioplasty, or angiographic evidence of significant ste

186 dial infarction (MI), coronary intervention (angioplasty, or coronary artery bypass surgery), angina

187 a post hoc analysis of the Second Medicine, Angioplasty, or Surgery Study (MASS II), which is a rand

188 luated for endarterectomy, balloon pulmonary angioplasty, or vasodilator therapies.

189 observed for most percutaneous transluminal angioplasty outcomes.

190 th late lumen loss showed superiority of DCB angioplasty over conventional balloon angioplasty.

191 graft and percutaneous transluminal coronary angioplasty (p<0.001 and p=0.005, respectively).

192 drug-coated balloon and 79.0% with standard angioplasty (P=0.005 for noninferiority).

193 5% CI: 50.0%, 73.0%) of conventional balloon angioplasty participants (P < .001).

194 5% CI: 66.5%, 86.0%) of conventional balloon angioplasty participants (P = .001).

195 DCB angioplasty and two conventional balloon angioplasty participants died (risk ratio, 0.48; 95% CI:

196 sful high-pressure percutaneous transluminal angioplasty, participants were randomly assigned to rece

197 randomly assigned to DCB (n=200) or standard angioplasty (percutaneous transluminal angioplasty [PTA]

198 was shown to be superior to standard balloon angioplasty (POBA) in terms of restenosis prevention for

199 s after paclitaxel drug-coated balloon (DCB) angioplasty, primary patency and freedom from target les

200 oronary artery bypass graft surgery/coronary angioplasty procedure/stent (1.35; 1.08-1.69), or any of

201 ess commonly in the others, with coarctation angioplasty procedures being the least successful (51%).

202 ntrol cohort of 81 patients who underwent 84 angioplasty procedures with conventional balloons.

203 We included 16 angioplasty procedures with retrievable stents in 13 pat

204 based clinics exceeded those of stenting and angioplasty procedures.

205 Balloon angioplasty produced a large decrease in both the noninv

206 ,837) and uncoated percutaneous transluminal angioplasty (PTA) (n = 143) were included.

207 imb ischemia using percutaneous transluminal angioplasty (PTA) and bail-out bare metal stenting (BMS)

208 ntion rates versus percutaneous transluminal angioplasty (PTA) and improve wound healing/limb preserv

209 pared the DES with percutaneous transluminal angioplasty (PTA) and provisional bare-metal stent (BMS)

210 DCB or an uncoated percutaneous transluminal angioplasty (PTA) balloon.

211 underwent balloon percutaneous transluminal angioplasty (PTA) between January 2009 and December 2012

212 ersus conventional percutaneous transluminal angioplasty (PTA) for the reduction of restenosis in dia

213 oated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic super

214 ty versus standard percutaneous transluminal angioplasty (PTA) in patients with femoropopliteal perip

215 raft and patient survival after percutaneous angioplasty (PTA) or stent placement for transplant rena

216 01) than those for percutaneous transluminal angioplasty (PTA), as were radiation exposures to the ha

217 term outcomes with percutaneous transluminal angioplasty (PTA), stent placement, atherectomy, or surg

218 er DCB or uncoated percutaneous transluminal angioplasty (PTA), we aggregated data from 2 RCTs compri

219 with conventional percutaneous transluminal angioplasty (PTA), yet durability of the treatment effec

220 tenting or percutaneous transluminal balloon angioplasty (PTA).

221 Paclitaxel-Coated Percutaneous Transluminal Angioplasty [PTA] Balloon Catheter vs Standard PTA for t

222 ndard angioplasty (percutaneous transluminal angioplasty [PTA]) (n=100).

223 ization with percutaneous transluminal renal angioplasty (PTRA) and stenting often fails to recover r

224 ransfer decreased neointimal formation in an angioplasty rat model by preventing vascular smooth musc

225 ed from the Swedish Coronary Angiography and Angioplasty Register between 2009 and 2013 and linked wi

226 mprehensive Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and end points evaluated th

227 included in the Swedish Coronary Angiography Angioplasty Registry (SCAAR) between 2006 and 2010 and w

228 part of the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).

229 l using the Swedish Coronary Angiography and Angioplasty Registry for enrollment.

230 the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) on all patients undergoing PCI (wi

231 the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

232 the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

233 wide SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

234 ered in the Swedish Coronary Angiography and Angioplasty Registry.

235 ted patients with MIS both in the setting of angioplasty-related MIS (area under the curve 0.94) and

236 ery disease, the long-term durability of DCB angioplasty remains uncertain.

237 rgeted pharmacotherapy and balloon pulmonary angioplasty represent potential therapeutic alternatives

238 DCB angioplasty resulted in sustained clinical and hemodynam

239 The torn wall was treated by patch angioplasty, resulting in a permanent IVC occlusion, as

240 disease burden was determined by the Bypass Angioplasty Revascularization Investigation (BARI) myoca

241 us and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (

242 The Bypass Angioplasty Revascularization Investigation 2 Diabetes (

243 (Bypass Angioplasty Revascularization Investigation 2 Diabetes [

244 essive Drug Evaluation; NCT00007657) (Bypass Angioplasty Revascularization Investigation 2 Diabetes [

245 omen and men enrolled in the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes)

246 oup, (n = 766 of 2,287), the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes)

247 cumented CAD enrolled in the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes)

248 with medical therapy in the BARI-2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes)

249 Aggressive Drug Evaluation], BARI 2D [Bypass Angioplasty Revascularization Investigation 2 Diabetes],

250 (Bypass Angioplasty Revascularization Investigation in Type 2 Di

251 eart disease and were enrolled in the Bypass Angioplasty Revascularization Investigation in Type 2 Di

252 (Bypass Angioplasty Revascularization Investigation in Type 2 Di

253 N-negative control subjects) from the Bypass Angioplasty Revascularization Investigation in Type 2 Di

254 t), clinical severity, type of intervention (angioplasty, stent, thrombolysis), clinical location (ho

255 Paclitaxel-eluting balloon (PEB) angioplasty, stenting, and directional atherectomy (DA)

256 Percutaneous transluminal renal angioplasty/stenting (PTRAS) is frequently used to treat

257 Portal vein angioplasty/stenting is conventionally performed through

258 part of a percutaneous transluminal balloon angioplasty strategy has equivalent 1-year patency and s

259 been due to the iteration and improvement of angioplasty technologies.

260 ation laboratory for guide wire crossing and angioplasty the next day.

261 n anterior STEMI patients undergoing primary angioplasty, the sooner IV metoprolol is administered in

262 least one invasive intervention (22 patients angioplasty/thrombolysis, 62 TIPS, and 20 OLT) and 36 (2

263 a step-wise approach using anticoagulation, angioplasty/thrombolysis, transjugular intrahepatic port

264 carotid arteries were injured using balloon angioplasty to cause neointimal hyperplasia.

265 e describe the technique of dialysis fistula angioplasty under ultrasound control.

266 gene transfer to arteries treated with stent angioplasty using a 2-source magnetic guidance strategy.

267 e or inhibit, respectively, restenosis after angioplasty, vein graft intimal thickening and atherogen

268 Percutaneous coronary angioplasty versus coronary artery bypass grafting in th

269 the superiority of drug-coated balloon (DCB) angioplasty versus standard percutaneous transluminal an

270 conditional Prkcd knockout mice, and carotid angioplasty was conducted in rats receiving transient Pr

271 series, PA stent fracture using UHP balloon angioplasty was feasible and did not result in major com

272 In drug-eluting stent ISR, balloon angioplasty was inferior to everolimus-eluting stent (0.

273 Balloon angioplasty was limited by unpredictable procedural outc

274 PCB angioplasty was more effective in BMS restenosis compare

275 Drug-coated balloon angioplasty was superior to standard angioplasty for the

276 In small randomized trials, PCB angioplasty was superior to uncoated balloon angioplasty

277 al, 738 STEMI patients reperfused by primary angioplasty were enrolled in 8 centers.

278 olar catheter or an alligator-clip-connected angioplasty wire.

279 of IH in various animal models (e.g. balloon angioplasty, wire injury, and vein graft), but very few

280 , bypass surgical procedures, and peripheral angioplasties with and without a stent.

281 cally significant atherosclerotic lesions to angioplasty with a paclitaxel-coated balloon or to stand

282 al artery disease, percutaneous transluminal angioplasty with a paclitaxel-coated balloon resulted in

283 Angioplasty with a retrievable stent is a safe and effic

284 consecutive patients undergoing endovascular angioplasty with a retrievable stent to treat vasospasm

285 due to an aneurysm treated with endovascular angioplasty with a retrievable stent.

286 12 months that was higher than the rate with angioplasty with a standard balloon.

287 successful percutaneous transluminal balloon angioplasty with an iodinated contrast medium (20 mL Iop

288 rate was low and did not differ between PCB angioplasty with and without additional BMS implantation

289 assigned to primary DES implantation or DCB angioplasty with bailout stenting after stratification f

290 A rabbit model of arterial angioplasty with local delivery of RvD2 (10 nM vs. vehic

291 The rate of peripheral angioplasty with or without a stent was higher among the

292 Angioplasty with PCB versus UCB reduces target lesion re

293 r-level factors, as well as the Stenting and Angioplasty With Protection in Patients at High Risk for

294 reased surgical risk, SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for

295 (Paclitaxel-Eluting Balloon Angioplasty With Provisional Use of Nitinol Stent Versus

296 and harms of percutaneous transluminal renal angioplasty with stent placement (PTRAS) versus medical

297 Angioplasty with stent placement is a therapeutic option

298 compression resulting in symptoms, although angioplasty with stenting may be used in recalcitrant ca

299 ary patency among patients who had undergone angioplasty with the drug-coated balloon was superior to

300 ficant reductions in pressure gradient after angioplasty, with no difference in postangioplasty gradi